Supplementary Materials

Supplementary Material for:

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

Gail M. Gauvreau, Jeffrey M. Harris,* Louis-Philippe Boulet, Heleen Scheerens, J. Mark Fitzgerald, Wendy S. Putnam, Donald W. Cockcroft, Beth E. Davis, Richard Leigh, Yanan Zheng, Barbro Dahlén, Yehong Wang, Romeo Maciuca, Irvin Mayers, X. Charlene Liao, Lawren C. Wu, John G. Matthews, Paul M. O'Byrne

*Corresponding author. E-mail: harris.jeffrey@gene.com

Published 2 July 2014, Sci. Transl. Med. 6, 243ra85 (2014)
DOI: 10.1126/scitranslmed.3008961

This PDF file includes:

  • Fig. S1. Mean serum concentration of quilizumab versus time in subjects with allergic rhinitis (phase 1b).
  • Fig. S2. Study design schema.
  • Fig. S3. Ratio of serum-specific IgE/total IgE in individual placebo- and quilizumab-treated (5.0 mg/kg, IV) allergic asthma subjects (phase 2a).
  • Fig. S4. Absolute levels of serum allergen-specific and total IgE over time in all individual subjects of placebo- and quilizumab-treated cohorts (phase 2a).
  • Fig. S5. Percentage of change of serum allergen-specific and total IgE levels over time in all individual subjects of placebo- and quilizumab-treated cohorts (phase 2a).
  • Fig. S6. Effect of quilizumab on serum allergen-specific IgE in allergic rhinitis subjects (phase 1b).
  • Fig. S7. IgE plasma cells in bone marrow aspirates of allergic asthma subjects (phase 2a).
  • Table S1. Pharmacokinetic parameters of quilizumab.
  • Table S2. Illustrative example of specific IgE data analysis.
  • Table S3. Predose baseline levels of all specific IgE (kU/liter) in the placebo-treated allergic asthma subjects.
  • Table S4. Predose baseline levels of all specific IgE (kU/liter) in the quilizumab-treated allergic asthma subjects.
  • Table S5. Individual subject serum total IgE (IU/ml) levels and summary statistics in placebo-treated allergic asthma subjects.
  • Table S6. Individual subject serum total IgE levels (IU/ml) and summary statistics in quilizumab-treated allergic asthma subjects.
  • Table S7. Individual subject serum total IgE (% baseline) levels and summary statistics in placebo-treated allergic asthma subjects.
  • Table S8. Individual subject serum total IgE levels (% baseline) and summary statistics in quilizumab-treated allergic asthma subjects.
  • Table S9. Individual subject serum challenge-specific IgE (kU/liter) levels and summary statistics in placebo-treated allergic asthma subjects.
  • Table S10. Individual subject serum challenge-specific IgE levels (kU/liter) and summary statistics of levels in quilizumab-treated allergic asthma subjects.
  • Table S11. Individual subject serum challenge-specific IgE (% baseline) levels and summary statistics in placebo-treated allergic asthma subjects.
  • Table S12. Individual subject serum challenge-specific IgE (% baseline) levels and summary statistics in quilizumab-treated allergic asthma subjects.
  • Table S13. Individual subject serum levels and summary statistics of non–challenge-specific IgE (kU/liter) levels in placebo-treated allergic asthma subjects.
  • Table S14. Individual subject serum levels and summary statistics of non–challenge-specific IgE (kU/liter) levels in quilizumab-treated allergic asthma subjects.
  • Table S15. Individual subject serum levels and summary statistics of non–challenge-specific IgE (% baseline) levels in placebo-treated allergic asthma subjects.
  • Table S16. Individual subject serum levels and summary statistics of non–challenge-specific IgE (% baseline) levels in quilizumab-treated allergic asthma subjects.

[Download PDF]